Joel Greenblatt's DXCM Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 13,554 shares of DexCom, Inc. (DXCM) worth $912,049, representing 0.00% of the portfolio. First purchased in 2014-Q2, this long-term strategic position has been held for 46 quarters.
Based on 13F filings since 2013, Joel Greenblatt has maintained a long-term strategic position in DXCM, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2020, adding 90,800 shares. Largest reduction occurred in Q2 2020, reducing 100,308 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's DexCom (DXCM) Holding Value Over Time
Track share changes against reported price movement
Quarterly DexCom (DXCM) Trades by Joel Greenblatt
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2014 | +32,132 | New Buy | 32,132 | $9.93 |
| Q3 2014 | -32,132 | Sold Out | 32,132 | $0.00 |
| Q4 2014 | +39,660 | New Buy | 39,660 | $13.77 |
| Q1 2015 | -39,660 | Sold Out | 39,660 | $0.00 |
| Q1 2018 | +40,160 | New Buy | 40,160 | $18.55 |
| Q2 2018 | -40,160 | Sold Out | 40,160 | $0.00 |
| Q4 2019 | +16,448 | New Buy | 16,448 | $54.66 |
| Q1 2020 | +90,800 | Add 552.04% | 107,248 | $67.32 |
| Q2 2020 | -100,308 | Reduce 93.53% | 6,940 | $101.30 |
| Q3 2020 | +3,944 | Add 56.83% | 10,884 | $103.09 |
| Q4 2020 | -3,940 | Reduce 36.20% | 6,944 | $92.45 |
| Q1 2021 | -6,944 | Sold Out | 6,944 | $0.00 |
| Q3 2021 | +2,848 | New Buy | 2,848 | $136.59 |
| Q4 2021 | +15,904 | Add 558.43% | 18,752 | $134.23 |
| Q1 2022 | +10,804 | Add 57.62% | 29,556 | $127.89 |
| Q2 2022 | -10,286 | Reduce 34.80% | 19,270 | $74.52 |
| Q3 2022 | +18,855 | Add 97.85% | 38,125 | $80.55 |
| Q4 2022 | +55,181 | Add 144.74% | 93,306 | $113.24 |
| Q1 2023 | -48,296 | Reduce 51.76% | 45,010 | $116.18 |
| Q2 2023 | -12,090 | Reduce 26.86% | 32,920 | $128.51 |
| Q3 2023 | +46,879 | Add 142.40% | 79,799 | $93.30 |
| Q4 2023 | -40,027 | Reduce 50.16% | 39,772 | $124.09 |
| Q1 2024 | -168 | Reduce 0.42% | 39,604 | $138.70 |
| Q2 2024 | +8,276 | Add 20.90% | 47,880 | $113.38 |
| Q3 2024 | +30,919 | Add 64.58% | 78,799 | $67.04 |
| Q4 2024 | +35,883 | Add 45.54% | 114,682 | $77.77 |
| Q1 2025 | -1,120 | Reduce 0.98% | 113,562 | $68.29 |
| Q2 2025 | -30,210 | Reduce 26.60% | 83,352 | $87.29 |
| Q3 2025 | -69,798 | Reduce 83.74% | 13,554 | $67.29 |
Joel Greenblatt's DexCom Investment FAQs
Joel Greenblatt first purchased DexCom, Inc. (DXCM) in Q2 2014, acquiring 32,132 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held DexCom, Inc. (DXCM) for 46 quarters since Q2 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's largest addition to DexCom, Inc. (DXCM) was in Q1 2020, adding 107,248 shares worth $7.22 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 13,554 shares of DexCom, Inc. (DXCM), valued at approximately $912,049. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, DexCom, Inc. (DXCM) represents approximately 0.00% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's peak holding in DexCom, Inc. (DXCM) was 114,682 shares, as reported at the end of Q4 2024. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.